This radiopharmaceutical is a catecholaminergic precursor, and it enters the cell through L-type amino acid transporter 1 and 2 (LAT1 and LAT2), which are overexpressed in tumor cells [2]. The gene discussed is SLC7A5; the disease is neoplasm.